Microchip Biotech: CS08399 Tablets Receive Drug Clinical Trial Approval Notice

Microchip Biotech Announcement: The wholly-owned subsidiary Chengdu Microchip Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration, approving the company’s product CS08399 tablets to conduct clinical trials.
CS08399 tablets are intended for the treatment of solid tumors and lymphomas with methionine adenosylphosphorylase (MTAP) deficiency.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin